These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 15279606)
1. Inhibition of endotoxin response by synthetic TLR4 antagonists. Hawkins LD; Christ WJ; Rossignol DP Curr Top Med Chem; 2004; 4(11):1147-71. PubMed ID: 15279606 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. Mullarkey M; Rose JR; Bristol J; Kawata T; Kimura A; Kobayashi S; Przetak M; Chow J; Gusovsky F; Christ WJ; Rossignol DP J Pharmacol Exp Ther; 2003 Mar; 304(3):1093-102. PubMed ID: 12604686 [TBL] [Abstract][Full Text] [Related]
3. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. Rossignol DP; Lynn M J Endotoxin Res; 2002; 8(6):483-8. PubMed ID: 12697095 [TBL] [Abstract][Full Text] [Related]
4. Endotoxin recognition molecules MD-2 and toll-like receptor 4 as potential targets for therapeutic intervention of endotoxin shock. Miyake K Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):291-7. PubMed ID: 15379597 [TBL] [Abstract][Full Text] [Related]
5. E5531, a pure endotoxin antagonist of high potency. Christ WJ; Asano O; Robidoux AL; Perez M; Wang Y; Dubuc GR; Gavin WE; Hawkins LD; McGuinness PD; Mullarkey MA Science; 1995 Apr; 268(5207):80-3. PubMed ID: 7701344 [TBL] [Abstract][Full Text] [Related]
6. Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers. Rossignol DP; Wong N; Noveck R; Lynn M Innate Immun; 2008 Dec; 14(6):383-94. PubMed ID: 19039062 [TBL] [Abstract][Full Text] [Related]
7. Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4-mediated signaling. Hyakushima N; Mitsuzawa H; Nishitani C; Sano H; Kuronuma K; Konishi M; Himi T; Miyake K; Kuroki Y J Immunol; 2004 Dec; 173(11):6949-54. PubMed ID: 15557191 [TBL] [Abstract][Full Text] [Related]
8. A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity. Hawkins LD; Ishizaka ST; McGuinness P; Zhang H; Gavin W; DeCosta B; Meng Z; Yang H; Mullarkey M; Young DW; Yang H; Rossignol DP; Nault A; Rose J; Przetak M; Chow JC; Gusovsky F J Pharmacol Exp Ther; 2002 Feb; 300(2):655-61. PubMed ID: 11805229 [TBL] [Abstract][Full Text] [Related]
9. Functionalized dendrimers as endotoxin sponges. Cromer JR; Wood SJ; Miller KA; Nguyen T; David SA Bioorg Med Chem Lett; 2005 Mar; 15(5):1295-8. PubMed ID: 15713373 [TBL] [Abstract][Full Text] [Related]
10. New insight in LPS antagonist. Ianaro A; Tersigni M; D'Acquisto F Mini Rev Med Chem; 2009 Mar; 9(3):306-17. PubMed ID: 19275723 [TBL] [Abstract][Full Text] [Related]
11. Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats. Kitazawa T; Tsujimoto T; Kawaratani H; Fukui H J Gastroenterol Hepatol; 2010 May; 25(5):1009-12. PubMed ID: 20546456 [TBL] [Abstract][Full Text] [Related]
12. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. Lynn M; Rossignol DP; Wheeler JL; Kao RJ; Perdomo CA; Noveck R; Vargas R; D'Angelo T; Gotzkowsky S; McMahon FG J Infect Dis; 2003 Feb; 187(4):631-9. PubMed ID: 12599080 [TBL] [Abstract][Full Text] [Related]
13. [Advances in the development of neutralizing therapies for sepsis]. Florencia Henning M; Garda H; Bakás L Medicina (B Aires); 2006; 66(3):263-73. PubMed ID: 16871917 [TBL] [Abstract][Full Text] [Related]